Stocktoria
PROVECTUS BIOPHARMACEUTICALS, INC. PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $336,108 at a -1615.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 2/9 | — | — | — |
| ALLR | Allarity Therapeutics, Inc. | 3/9 | — | — | — |
| HIND | Vyome Holdings, Inc | 3/9 | — | — | — |
| ABVC | ABVC BIOPHARMA, INC. | 3/9 | -13.52 | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
| SCNX | Scienture Holdings, Inc. | 4/9 | -0.88 | — | — |
| CLNN | Clene Inc. | 1/9 | — | — | — |
About PROVECTUS BIOPHARMACEUTICALS, INC.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
FAQ
Is PVCT financially healthy?
PROVECTUS BIOPHARMACEUTICALS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does PVCT pay a dividend?
No, PROVECTUS BIOPHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is PVCT?
In FY2025, PROVECTUS BIOPHARMACEUTICALS, INC. had a net margin of -1615.8%.
Is PVCT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PROVECTUS BIOPHARMACEUTICALS, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.